The venture capital firm Clave Capital closed 2025 consolidating its activity as a national benchmark in Tech Transfer and Deep Tech, managing over €100M. In addition, it continues its investment and divestment activity across its funds and has launched a new corporate fund in which it has already made the first investments.
The firm maintains a clear commitment to valuing IP generated in innovative technological environments, both linked to scientific research (universities, technology centers, etc.) and other contexts.
Thanks to over 20 years of experience in the sector and its positioning, throughout 2025 Clave Capital completed 5 divestments with an average capital multiple of 4.0x, confirming its ability to generate value in Tech Transfer and Deep Tech investments.
These divestments materialized after an average holding period of 5.5 years, supporting founding teams and demonstrating market interest and the potential of their technological developments in areas such as health sciences (Abanza Tecnomed), quantum AI (Multiverse), and materials (Aerox). These divestments also confirm its ability to accompany companies through to solid liquidity events in Series A and later stages.
The divestments were carried out with industrial and financial investors, as well as public offerings, enabling these companies to continue developing their growth and value creation strategies with new partners.
At the same time, over the past year, Clave Capital made 12 new investments and 23 follow-ons, committing a total of €12M in key sectors such as Health, Food Tech, and Deep Tech, with ticket sizes ranging from €150,000 to €2,000,000, highlighting investments in Aortyx and Nanoligent. All of these investments have a clear market focus and leverage differentiated technologies.
These 35 investment rounds attracted equity and convertible loans totaling €72M, from both domestic and international investors, confirming the capacity of these companies to generate trust and future value.
Moreover, all these decisions follow Clave’s investment thesis: a commitment to technology transfer and its profitability in the venture capital space. Beyond capital, the team believes in the value of hands-on support and works closely with portfolio companies.
At Clave Capital, they continue to support ambitious founding teams with scalable business models, alongside domestic and international co-investors. Their goal is not only to invest but also to help build stronger companies better prepared to compete in the long term
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
